V
Valbiotis
Biotech & Life Sciences · Perigny, France · Founded 2014 · IPO 2017
Solutions for cardio-metabolic diseases prevention MoreLess
Valbiotis is a research and development company focused on addressing metabolic diseases through scientific innovation. The company operates in the healthcare sector, targeting unmet medical needs with a pipeline of proprietary compounds, including TOTUM 63, TOTUM 070, TOTUM 854, and TOTUM 448. Valbiotis collaborates with global partners, such as HEALTH SCIENCE, to develop and commercialize its products. The business model revolves around advancing these compounds through clinical trials and securing strategic partnerships for commercialization. Valbiotis serves healthcare professionals, investors, and the general public, aiming to provide effective solutions for conditions like hypercholesterolemia and diabetes. The company generates revenue through partnerships and potential product sales upon successful market entry. Valbiotis actively participates in scientific events and publications to maintain its presence in the research community.
Talent graph
Valbiotis's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Valbiotis's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Valbiotis has talent and traffic
team presence
Market sentiment
What the market is saying about Valbiotis
An AI-synthesized read of the highest-engagement posts about Valbiotis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Valbiotis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.